Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06084884 · ClinicalTrials.gov registry record · Phase 1
A Phase I/II Study to Evaluate AZD5851 in GPC3+ Advanced/Recurrent Hepatocellular Carcinoma
A Phase 1 study of Hepatocellular Carcinoma, sponsored by AstraZeneca.
- Active
- Registry status
- Phase 1
- Development phase
- 94
- Enrollment target
- 18
- Study locations
NCT06084884 is a Phase 1 study of Hepatocellular Carcinoma that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 94 participants, below the 257-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (63% lower). The trial reports 18 study locations across 13 states.
The verdict
NCT06084884, a Phase 1 study of Hepatocellular Carcinoma, is active but no longer recruiting, sponsored by AstraZeneca.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 94 participants
- Enrollment target
- 18
- Study locations
Study Summary
A Phase I/II study to evaluate AZD5851 in patients with GPC3+ advanced/recurrent hepatocellular carcinoma.
Conditions Studied
Interventions
- BIOLOGICAL AZD5851
Study Locations (18)
California
- Research Site - Duarte
- Research Site - Orange
- Research Site - San Francisco
Other
- Research Site - Kashiwa
- Research Site - Osakasayama-shi
- Research Site - Seoul
Pennsylvania
- Research Site - Philadelphia
- Research Site - Pittsburgh
Arizona
- Research Site - Phoenix
District of Columbia
- Research Site - Washington D.C.
Florida
- Research Site - Jacksonville
Georgia
- Research Site - Atlanta
Kansas
- Research Site - Westwood
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 94 participants |
| Start Date | 2023-12-14 |
| Est. Completion | 2027-12-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06084884
The ClinicalTrials.gov registry entry for NCT06084884 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 94 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 257-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (63% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hepatocellular Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which AZD5851 is the first listed.
NCT06084884 reports 18 study locations spanning 13 distinct geographic areas - top geographies include California, Other, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06084884 about?
NCT06084884 is a clinical study titled "A Phase I/II Study to Evaluate AZD5851 in GPC3+ Advanced/Recurrent Hepatocellular Carcinoma". A Phase I/II study to evaluate AZD5851 in patients with GPC3+ advanced/recurrent hepatocellular carcinoma.
What is the current status of trial NCT06084884?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 94 participants. The study started on 2023-12-14. Estimated completion is 2027-12-13.
What conditions does trial NCT06084884 study?
This clinical trial studies the following conditions: Hepatocellular Carcinoma.
What interventions are being tested in trial NCT06084884?
The interventions under investigation include: AZD5851 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06084884?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06084884 being conducted?
This trial has 18 study locations across Arizona, California, District of Columbia, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatocellular Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
RECRUITING · Phase 1
-
Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells
RECRUITING · Phase 1
-
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
RECRUITING · Phase 1
-
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients
RECRUITING · Phase 1
-
Cryoablation and Arterial Infusion of SD-101 in Combination with Durvalumab and Tremelimumab
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.